Compare Redwire Corporation (RDW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Redwire Corporation trades at $9.58 (market cap $2.44B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 31.2× Redwire Corporation's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| RDW | REGN | |
|---|---|---|
Market Cap | $2.44B | $76.14B |
Volume | 11,053,212 | 500,239 |
Sector | Industrials | Health |
52-Week High | $25.90 | $852.03 |
52-Week Low | $5.06 | $557.73 |
Typical Hold Time | 18 Days | 107 Days |
Enterprise Value | $1.97B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDW trades at $9.76, down 4.69% on the day, reflecting a bearish technical trend. The company reported a net loss of $226.55M in 2025, with a negative net margin of -57.26%, though revenue grew to $335.38M. Recent news highlights strategic partnerships, including a $981M Space Force contract and collaborations with Honda and Sophia Space on robotics and orbital data centers, signaling growth potential in the space infrastructure sector.
The outlook is mixed: strong analyst consensus (80% buy ratings) and a $14.88 price target suggest upside, but persistent losses, negative cash flow from operations, and dependence on SpaceX's success pose significant risks. Investors face high volatility amid speculative growth prospects in the evolving space economy.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
